We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Recursion Pharmaceuticals (RXRX) Advances While Market Declines: Some Information for Investors
Read MoreHide Full Article
Recursion Pharmaceuticals (RXRX - Free Report) closed the most recent trading day at $3.37, moving +1.51% from the previous trading session. This move outpaced the S&P 500's daily loss of 0.28%. Elsewhere, the Dow saw a downswing of 0.44%, while the tech-heavy Nasdaq depreciated by 0.28%.
Heading into today, shares of the biotechnology company had lost 5.95% over the past month, outpacing the Medical sector's loss of 7.53% and lagging the S&P 500's loss of 3.59%.
The investment community will be paying close attention to the earnings performance of Recursion Pharmaceuticals in its upcoming release. On that day, Recursion Pharmaceuticals is projected to report earnings of -$0.27 per share, which would represent year-over-year growth of 46%. At the same time, our most recent consensus estimate is projecting a revenue of $20.73 million, reflecting a 40.65% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$0.93 per share and revenue of $90.52 million, which would represent changes of +35.42% and +21.21%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Recursion Pharmaceuticals. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 9.98% higher. As of now, Recursion Pharmaceuticals holds a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 142, putting it in the bottom 43% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Recursion Pharmaceuticals (RXRX) Advances While Market Declines: Some Information for Investors
Recursion Pharmaceuticals (RXRX - Free Report) closed the most recent trading day at $3.37, moving +1.51% from the previous trading session. This move outpaced the S&P 500's daily loss of 0.28%. Elsewhere, the Dow saw a downswing of 0.44%, while the tech-heavy Nasdaq depreciated by 0.28%.
Heading into today, shares of the biotechnology company had lost 5.95% over the past month, outpacing the Medical sector's loss of 7.53% and lagging the S&P 500's loss of 3.59%.
The investment community will be paying close attention to the earnings performance of Recursion Pharmaceuticals in its upcoming release. On that day, Recursion Pharmaceuticals is projected to report earnings of -$0.27 per share, which would represent year-over-year growth of 46%. At the same time, our most recent consensus estimate is projecting a revenue of $20.73 million, reflecting a 40.65% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$0.93 per share and revenue of $90.52 million, which would represent changes of +35.42% and +21.21%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Recursion Pharmaceuticals. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 9.98% higher. As of now, Recursion Pharmaceuticals holds a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 142, putting it in the bottom 43% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.